Amyloids are the substance made up of abnormally formed protein in the bone marrow that gets saturated in different tissues or organs of the body. The condition is termed as amyloidosis. Amyloidosis is a clinical disorder caused by extracellular and/or intracellular deposition of insoluble abnormal amyloid fibrils that alter the normal function of tissues. Systemic amyloidosis (AL amyloidosis or just primary amyloidosis) is a medical condition which involves the mesenchymal tissue, the tongue, heart, gastrointestinal tract, and skin. Globally increasing awareness about systemic amyloidosis amongst people and increasing investment by companies to develop effective and new treatments is expected to drive the global demand for systematic amyloidosis market during the period of study.
This report identifies the global systemic amyloidosis market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to systemic amyloidosis market.
Geographically, North America dominated the systemic amyloidosis market due to because of high awareness, higher percentage of total income spent on healthcare compared to other economies and appropriate reimbursement circumstances and well developed healthcare infrastructure. North America was followed by Europe and Asia-Pacific as the second and third largest consumer of systemic amyloidosis. Asia Pacific is projected to have the fastest growth, owing to rapidly expanding healthcare infrastructure, increasing awareness especially in the major regional economies such as India and China in the region.
This report segments systemic amyloidosis market on the basis of type and regional market as follows:
- On the basis of type this report on systemic amyloidosis market is segmented as follows, covering major segments type as follows: Primary systemic amyloidosis (PSA), Amyloidosis associated with multiple myelomam, Secondary systemic amyloidosis and others
- This report on systemic amyloidosis has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the systemic amyloidosis market. Some of the major companies’ profiles in detail are as follows:
- Celgene Corporation
- Prothena Corporation Plc
- TheraPharm Deutschland GmbH
- Johnson & Johnson
- Onclave Therapeutics Limited Llc